[Recent pharmacologic aspects of sulfamides modifying insulin secretion (hypoglycemic and hyperglycemic sulfamides)].
D000818:Animals; D002395:Catecholamines / Q000097:blood; D003981:Diazoxide / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D004357:Drug Synergism; D005947:Glucose / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology*; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010180:Pancreatectomy; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D014044:Tolbutamide / Q000494:pharmacology*
D002395:Catecholamines; D007328:Insulin; D010643:Phenoxybenzamine; D014044:Tolbutamide; D011433:Propranolol; D005947:Glucose; D007545:Isoproterenol; D003981:Diazoxide; D005905:Glyburide
Aspects pharmacologiques récents concernant les sulfamides modificateurs de la sécrétion d'insuline (sulfamides hypoglycémiants et sulfamides hyperglycémiants)